Home/Pipeline/Platform Vaccine Applications

Platform Vaccine Applications

Infectious Diseases

DiscoveryResearch

Key Facts

Indication
Infectious Diseases
Phase
Discovery
Status
Research
Company

About Chimeron Bio

Chimeron Bio is a private, pre-clinical stage biotech based in Philadelphia, developing a transformative platform for in-vivo genetic medicine. Its core innovation, the ChaESAR™/MultiPlex™ platform, utilizes self-amplifying RNA to deliver large, multi-gene payloads directly to patients, enabling weeks-long expression for complex therapies like CAR-T without ex vivo manufacturing. The company is advancing a pipeline in oncology and autoimmunity, has secured notable NIH grant funding and strategic manufacturing partnerships, and is led by a seasoned team with deep RNA and biotech experience, including a former Moderna CSO on its board.

View full company profile

Other Infectious Diseases Drugs

DrugCompanyPhase
Next-generation mRNA VaccinesBioNTechPhase 1
Genetic Molecular TestsEurobio ScientificCommercial
LEAPS TechnologyCEL-SCIPre-clinical